Pfizer Inc. PFE announced positive top-line data from a phase IIa study evaluating its JAK3 inhibitor candidate, PF-06651600, and tyrosine kinase 2/JAK1 inhibitor, PF-06700841, as a treatment for moderate to severe alopecia areata (“AA”).
Both the candidates met the primary endpoint of improving hair regrowth on the scalp compared to baseline over 24 weeks of treatment. Data from the study was presented at the European Academy of Dermatology and Venereology Congress, which was held in France.
The neuroscience technology company Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, today announced its voice biomarker and AI platform, NeuroVocalixâ, for use in clinical trials.
Having filed patents and announced the start of the technology programme last year, the Company has now confirmed its first voice-based cognitive assessments are available for use in its core pharmaceutical and biotechnology clinical trial channels.